The Wyss Institute and the U.S. Defense Advanced Research Projects Agency (DARPA) have signed an agreement worth up to $16 million over the next year to use Wyss technologies to identify and test FDA-approved drugs that could be repurposed to prevent or treat COVID-19. Specifically, DARPA will use the computational drug-discovery pipelines and human organ chip technologies developed by the Wyss Institute for Biologically Inspired Engineering at Harvard University. (For more on how organ chip technologies work, listen to UMR’s Amazing Things Podcast episode “a conversation with NCAT’s Dr. Lucie Low” – listen here.)
